Oxford Biomedica PLC — Major Shareholding Notification 2014

Jun 18, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 9095J

Oxford Biomedica PLC

18 June 2014

For filings with the FCA include the annex
For filings with issuer exclude the annex
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii				Oxford BioMedica plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights					√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):	CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING AND OPEN OFFER				√
3. Full name of person(s) subject to the notification obligation: iii		Aviva plc & its subsidiaries
4. Full name of shareholder(s) (if different from 3.):iv		Registered Holder: BNY Norwich Union Nominees Limited    5,784,937* Chase (GA Group) Nominees Limited    190,538,969*             * denotes direct interest    Chase (GA Group) Nominees Limited      16,452,188 Chase Nominees Limited                               6,676,094 Vidacos Nominees Limited                          20,547,812
5. Date of the transaction and date on which the threshold is crossed or reached: v		17 June 2014
6. Date on which issuer notified:		18 June 2014
7. Threshold(s) that is/are crossed or reached: vi, vii		0% to 7% Change at Direct Interest Level and 0% to >5% Change at Combined Interest Level

8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of shares if possible using the ISIN CODE	Situation previous to the triggering transaction						Resulting situation after the triggering transaction
Number of Shares			Number of Voting Rights			Number of shares	Number of voting rights			% of  voting rights x
Direct	Direct xi		Indirect xii	Direct			Indirect
Ordinary Shares GB00066458157	Nil Held			Nil Held			240,000,000	196,323,906		43,676,094	7.87%			1.75%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument			Expiration date xiii		Exercise/ Conversion Period xiv				Number of voting rights that may be acquired if the instrument is exercised/ converted.				% of voting rights
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial instrument		Exercise price		Expiration date xvii		Exercise/ Conversion period xviii		Number of voting rights instrument refers to				% of voting rights xix, xx
												Nominal			Delta

Total (A+B+C)
Number of voting rights	Percentage of voting rights
240,000,000	9.62%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- Aviva Investors Global Services Limited: ·      Aviva plc (Parent Company) ·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) ·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) ·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:
13. Additional information:	Figures are based on on a revised total number of voting rights of 2,494,584,919 as per the Company's Results of Firm Fundraising and Open Offer Announcement of 16 June 2014.
14. Contact name:	Tim Watts, Oxford BioMedica PLC
15. Contact telephone number:	01865 783000

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLUWOWRSVANARR